Table 5. Clinical relevance of aGP2 and ASCA with disease characteristics in patients with Crohn’s disease.

Parameters	IgG aGP2	IgA aGP2	aGP2 either	aGP2 both	IgG ASCA	IgA ASCA	ASCA either	ASCA both	ASCA+\aGP2- a	ASCA-\aGP2+ a	ASCA-\aGP2- a
Age at diagnosis b	0.039					0.014
A3	0.011 0.4 (0.2, 0.8)		0.045 0.5 (0.2, 1.0)				0.035 0.4(0.2, 1.0)		0.041 0.4 (0.1, 0.9)		0.019 2.4 (1.1, 5.0)
L1		0.022 2.4 (1.1, 5.0)	0.022 2.4(1.1, 5.2)								0.003 0.2 (0.1, 0.6)
L3		0.033 0.5 (0.3, 0.9)						0.011 2.9(1.2, 7.0)	0.041 2.0 (1.0, 3.8)
B2						0.018 0.4 (0.2, 0.9)
B3	0.027 2.1 (1.1, 3.9)	0.042 2.0 (1.0, 3.8)	0.032 2.0 (1.1, 3.8)	0.026 2.2 (1.1, 4.4)	0.020 2.2 (1.1, 4.2)			0.022 2.4(1.1, 5.3)			0.009 0.4 (0.2, 0.8)
P	0.003 2.6 (1.4, 4.8)		0.015 2.2 (1.2, 4.1)
Dermatologic									0.030 0.3 (0.1, 0.9)
Steroids resistance								0.047 3.1(1.0, 10.0)

Clinical relevance of the markers with disease characteristics in patients with Crohn’s disease expressed as P-Values and OR (95% confidence interval, CI). Only significant relevance for a given parameter by χ² test is shown. Positive associations are indicated in bold and negative associations in italic (P-Values, odds ratio and range). A represents age at diagnosis (A3, above 40 years), L represents the location of disease (L1, ileal; L3, ileocolonic), and B represents disease behavior (B2, stricturing; B3, penetrating; p, perianal disease modifier) based on the Montreal Classification. ASCA, anti-Saccharomyces cerevisiae antibody; aGP2, anti-zymogen granule glycoprotein 2 antibodies.

^aASCA +, ASCA either; aGP2 +, aGP2 either; ASCA -, both ASCA IgA and ASCA IgG negative; aGP2 -, both aGP2 IgA and aGP2 IgG negative.

^bThe correlation between age at diagnosis with the antibodies was assessed with Spearman's rank correlation coefficient.